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Abstract - Defibrillation threshold testing (DFT) is a standard procedure during implantable cardioverter defibrillator 
(ICD) implantation, however, it is not without risks. We compared the one-year follow-up period in ICD-implanted pa-
tients, with and without DFT performed during implantation, for preventive indication in regard to appropriate and 
inappropriate ICD detection and therapy. One group consisted of 20 patients without DFT; another was comprised of 20 
patients where DFT had been performed. There was no difference in the development of ventricular tachyarrhythmias be-
tween the groups. Appropriate therapy of ICD was 100%. DFT is not a predictor for successful ICD detection and therapy 
of ventricular tachyarrhythmias.
Key words: Implantable cardioverter defibrillator, defibrillation threshold testing, sudden cardiac death, primary preven-
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INTRODUCTION
Defibrillation threshold testing (DFT) is performed 
by  inducing  ventricular  fibrillation  (VF)  during 
implantable  cardioverter  defibrillator  (ICD)  im-
plantation,  to  ensure  reliable  sensing,  detection, 
and  defibrillation,  and  it  has  been  implemented 
for more than two decades (Liu et al., 2009). To-
day ICD technology, as well the algorithms for the 
diagnosis  and  treatment  of  ventricular  tachyar-
rhythmias  (ventricular  tachycardia/ventricular 
fibrillation-VT/VF)  have  advanced,  making  ICD 
therapy more reliable (Calvi et al., 2010). Bearing 
in mind that DFT is not without some risks, such 
as embolic stroke in patients with atrial fibrillation, 
myocardial damage assessed through a troponin 
rise (Liu et al., 2009), transient depression of left 
systolic function and prolonged asystole (Kolb et 
al., 2006), (Frame et al., 1992), and DFT-related 
deaths, there is an on-growing demand in the sci-
entific community to reassess the need for DFT 
during  ICD  implantation  (Strickberger,  2004), 
(Neuzner, 2005).
The aim of this study was to compare the one-
year follow-up period in ICD implanted patients (i.e. 
one  group  without  DFT  during  implantation  and 
one group with) for preventive indication related to 
appropriate  and  inappropriate  ICD  detection  and 
therapy.466 NATAŠA KOVAČEVIĆ-KOSTIĆ ET AL.
MATERIALS AND METHODS
Patient selection
Our study was a single-center, randomized trial. Pa-
tients undergoing ICD implantation for primary pre-
vention according to the official guidelines of ACC/
AHA/ESC/EHRA, 2008 (Zipes et al., 2006), (Epstein 
et al., 2008), (Wilkoff et al., 2008), (Dickstein et al., 
2010) between December 2006 and June 2010 were 
included in our study. Data analysis was performed 
after the last 12-month follow-up in June 2011. The 
investigation conformed to the principles outlined in 
the Declaration of Helsinki (Br Med J 1964; ii: 177). 
All patients provided written informed consent, as 
approved by the Institutional Review Board, for data 
collection, management, and analysis. They were di-
vided randomly 1:1 into two groups. These were as 
follows: a group comprised of patients that did not 
have DFT and which will be referred to as the “no-
DFT-group”, and a group of patients who had DFT 
and that was referred to as the “DFT-group”.
ICD implantation and Defibrillation  
Threshold Testing
All ICDs were implanted at the Clinical Center of 
Serbia. A ventricular lead was introduced through 
the left cephalic vein or left subclavian vein, which 
was used as an alternative site of lead implantation. 
The standard protocol for VT/VF treatment in im-
planted ICDs allows the detected ventricular tachy-
cardia (heart rate less than 180 beats/min) to be treat-
ed with the least aggressive therapy – antitachycardia 
“burst”’ therapy (ATP). If a series of repeated ATP 
does not terminate ongoing tachycardia, low power 
(0.1-5J) synchronous cardioversion (CD) is the next 
therapy of choice by algorithm, and if this is futile, 
ICD delivers a defibrillating (DC) shock of maximal 
power (29-36J) (Milašinović, 2007). If the ventricular 
tachyarrhythmia is with a heart rate greater than 188 
beats/min, ICD instantly delivers a DC shock. Also, 
these  ICDs  have  antibradycardia  pacing.  In  some 
patients, this is indicated at the implantation due to 
the nature of their disease, while in others this is a 
so-called “reserve therapy”, because antibradycardia 
pacing is usually necessary after DC, when short car-
diac arrest is registered. 
Defibrillation threshold testing was performed 
during  a  short-term  intravenous  anesthesia  using 
propofol or hypnomidate, by a method of 10 J volt-
age difference between a device’s maximal DC shock 
and  the  obtained  successful  defibrillation  voltage. 
The follow-up of ICD patients was performed at 1, 3, 
6 and 12 months post implantation at our outpatient 
clinic. These visits included device interrogation and 
analysis of the printouts for appropriate and inap-
propriate therapy (shock delivery) in all implanted 
patients, as well as a check-up of the ICD device bat-
tery status. 
Statistical analysis
The normality assumption for continuous variables 
was  evaluated  by  the  Kolmogorov-Smirnov  test. 
Continuous  variables  are  presented  as  means  and 
standard  deviations  for  normally  distributed  vari-
ables or as a median and interquartile range for non-
distributed ones. They were compared using Student’s 
unpaired t test or the Mann-Whitney rank sum test, 
as appropriate. Categorical variables are presented as 
counts and percentages and were compared with the 
chi-square  when  appropriate  (expected  frequency 
>5). Otherwise, Fisher’s exact test was used. For all 
analyses, a two-sided p<0.05 was considered statisti-
cally significant.
The  probability  of  the  outcome  of  events  was 
calculated using the Kaplan Meier method, and dif-
ferences between these curves were analyzed by the 
long-rank test. The interactions of each of the factors 
(observed in this study, including DFT), and their 
effect on the probability of rhythm disturbance oc-
currence were analysed using the Cox proportional 
hazards model. All data were processed with the sta-
tistical package for social sciences, version 17 (SPSS, 
Chicago, Ill).
RESULTS
Forty  patients  underwent  ICD  treatment  for  pri-DEFIBRILLATION THRESHOLD TESTING 467
mary prevention of sudden cardiac death and were 
included in our study. The mean age of the tested 
population  was  58±14  years,  and  predominantly 
male (82%). The no-DFT-group consisted of 20 pa-
tients of whom 80% were males, the mean age of 
the patients was 56±13.3 years, while 20 patients in 
the DFT-group were 59±14.9 years of age; 85% were 
male. There were no statistical significant differences 
in the frequencies of the evaluated demographic pa-
rameters (Table 1).
Our  results  showed  no  statistically  significant 
difference  in  the  development  of  VT/VF  between 
the two groups registered at all follow-up visits per-
formed 1, 3, 6, and 12 months after ICD implanta-
tion. At 1-month and 3-months of follow-up, in the 
DFT-group VT/VF occurred in 1 (5%) patient vs. 2 
(10%) patients in the no-DFT-group (p=0.99). At the 
6-month follow–up, VT/VF did not occur in any of 
the patients in the no-DFT-group, while it occurred 
in  2  (10%)  patients  in  the  DFT-group  (p=0.487). 
VT/VF occurred in 4 (20%) patients in the no-DFT-
group vs. 1 (5%) patient in the DFT-group (p=0.342) 
at 12-months of follow-up. If we divide ventricular 
tachyarrhythmias on VT and VF, the results show 
that at 1-months follow–up, in the DFT-group VT 
occurred in 1 (5%) patient, while in the no-DFT-
group VT occurred in 2 (10%) patients. There was 
no VF noted in any of the patients (p=0.548). At 
3-months follow-up, in the no-DFT-group VF devel-
oped in 1 (5%) patient; VT also developed in 1 (5%) 
patient. In the DFT-group there was no registered 
Table 1. Patients’ baseline characteristics.
Total
(n=40)
DFT not performed
(n=20)
DFT performed
(n=20)
P
Male, n (%) 33 (82) 16 (80) 17 (85) 1.00
Age, years (SD) 58 (14.0) 56 (13.3) 59 (14.9) 0.499
Diabetes, n (%) 9 (23) 3 (16) 6 (30) 0.451
Hypertension, n (%) 24 (60) 12 (60) 12 (60) 0.744
Dyslipidemia, n (%) 25 (62.5) 12 (60) 13 (65) 1.00
ICMP, n (%) 28 (70) 13 (65) 15 (75) 0.490
Non-ischemic CMP, n (%) 12 (30) 7 (35) 5 (25) 0.731
Previous MI, n (%) 24 (60) 9 (45) 15 (75) 0.053
LBBB/RBBB, n (%) 8 (20) 5 (25) 3 (15) 0.695
Digoxin, n (%) 7 (17.5) 5 (25) 2 (10) 0.407
Amiodarone, n (%) 28 (70) 14 (70) 14 (70) 1.00
ß blockers, n (%) 38 (95) 18 (90) 20 (100) 0.487
ACE inh, n (%) 34 (85) 16 (80) 18 (90) 0.661
Statins, n (%) 29 (72.5) 14 (70) 15 (75) 0.99
ICD Type, n (%)
0.661
VR 34 (85) 16 (80) 18 (90)
DR 6 (15) 4 (20) 2 (10)
Ejection fraction, % (IQR) 27.0 (12) 30.0 (16.0) 26.0 (4) 0.181
NYHA, n (%)
I
II
III
31(77,5)
6 (15)
3 (7,5)
16 (80,0)
2 (10)
2 (10)
15 (75,0)
4 (20)
1 (5)
0.59
ICMP- Ischemic Cardiomyopathy; IM- Myocardial Infarction; LBBB- Left Bundle Branch Block; RBBB- Right Bundle Branch Block; 
IQR- interquartile range; NYHA- New York Heart Association468 NATAŠA KOVAČEVIĆ-KOSTIĆ ET AL.
VF, while VT developed in 1 (5%) patient (p= 0.598). 
At 6-months follow-up VF did not develop in any of 
the patients, while VT developed in 2 (10%) patients 
in the DFT-group (p=0.487). At 12-months follow-
up VF developed in 4 (20%) patients in the no-DFT-
group, while in the DFT-group VF was not registered. 
In the DFT-group, VT developed in 1 (5%) patient, 
while in the no-DFT-group VT was not registered 
(p=0.072). All VT episodes in both groups were suc-
cessfully terminated with burst therapy (ATP), while 
all VF episodes were terminated with a single DC 
shock, showing that therapy effectiveness was 100%. 
Throughout the period of follow-up in our popula-
tion, VT/VF developed 13 times (VT developed 8 
Table 2. VT/VF occurrence at 1, 3, 6, and 12-month follow-ups.
Total
(n=40)
DFT not performed
(n=20)
DFT performed
(n=20)
p
VT/VF 1.month follow up, n (%)      3 (7.5) 2 (10) 1 (5) 0.99
VT1.month follow up, n (%) 3 (7.5) 2 (10) 1 (5)
0.548
VF 1.month follow up, n (%) 0 (0) 0 (0) 0 (0)
VT/VF 3.month follow up, n (%) 3 (7.5) 2 (10) 1 (5) 0.99
VT 3.month follow up, n (%) 2 (5) 1 (5) 1 (5)
0.598
VF 3.month follow up, n (%) 1 (2.5) 1 (5) 0 (0)
VT/VF 6.month follow up, n (%) 2 (5) 0 (0) 2 (10) 0.487
VT 6.month follow up, n (%) 2 (5) 0 (0) 2 (10)
0.487
VF 6.month follow up, n (%) 0 (0) 0 (0) 0 (0)
VT/VF 12.month follow up, n (%) 5 (12.5) 4 (20) 1 (5) 0.342
VT 12.month follow up, n (%) 1 (2.5) 0 (0) 1 (5)
0.072
VF 12.month follow up, n (%) 4 (10) 4 (20) 0 (0)
VT- ventricular tachycardia; VF- ventricular fibrillation
Table 3. NSVT occurrence at 1, 3, 6, and 12-month follow-ups
Total
(n=40)
DFT not performed
(n=20)
DFT performed
(n=20)
p
NSVT 1.month follow up, n (%) 7 (17.5) 2 (10) 5 (25) 0.407
NSVT 3.month follow up, n (%) 9 (22.5) 4 (20) 5 (25) 0.99
NSVT 6.month follow up, n (%) 12 (30) 6 (30) 6 (30) 0.99
NSVT 12.month follow up, n (%) 14 (35) 10 (50) 4 (20) 0.097
NSVT – non-sustained ventricular fibrillation
Table 4. AF occurrence at 1, 3, 6, and 12-month follow-ups
Total
(n=40)
DFT not performed
(n=20)
DFT performed
(n=20)
p
AF 1.month follow up, n (%) 9 (22.5) 3 (15) 6 (30) 0.451
AF 3.month follow up, n (%) 8 (20) 2 (10) 6 (30) 0.235
AF 6.month follow up, n (%) 9 (22.5) 3 (15) 6 (30) 0.451
AF 12.month follow up, n (%) 8 (20) 2 (10) 6 (30) 0.235
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times, VF 5 times). In addition, the development of 
non-sustained ventricular tachycardia (NSVT) and 
atrial fibrillation (AF) did not statistically differ be-
tween the no-DFT-group and the DFT-group at 1, 3, 
6, and 12-months of follow-up. Appropriate therapy 
(ATP or DC shock) deliverance of ICD was 100%. 
Over a one-year period, 9 (22.5%) patients devel-
oped VT/VF, while 31 (77.5%) patients did not de-
velop VT/VF at all (p=0.001) (Tables 2, 3, 4). 
The Kaplan Meier analysis showed a statistically 
significant  difference  between  the  DFT-  and  no-
DFT-groups in probability, without rhythm distur-
bance occurrence for VF development (VF did not 
occur at all during the 12-month follow-up in the 
DFT performed group) (p=0.037). All VF episodes 
that occurred in the no-DFT-group were successful-
ly terminated with a single DC shock. Kaplan Meier 
analysis did not show a statistically significant differ-
ence between groups with respect to the probabil-
ity without rhythm disturbance occurrence for VT, 
NSVT and AF, which indicates good randomization 
(Table 5, Fig. 1).
Cox  Regression  analysis  pointed  out  prior 
ischemia as a predictor of difference in probability 
for developing NSVT, while for all events (regardless 
of the type of rhythm disturbance) the predictor of 
difference was digoxin therapy, meaning that patients 
that were not on digoxin did not develop any of the 
rhythm  disturbances  within  the  12-month  period 
of observation. In addition, Cox regression analysis 
showed digoxin therapy as a predictor of difference 
in probability for developing VF. The Cox regression 
model did not establish DFT as a predictor of event 
occurrence.
DISCUSSION
In our study, during a one-year follow-up we did not 
detect any statistically significant differences in the 
development of VT/VF, NSVT and AF between the 
no-DFT- and DFT-groups. Thirteen episodes of VT/
VF (8 episodes of VT, and 5 episodes of VF) were de-
tected in 22.5% of our study population in the course 
of one year. Adequate therapy was delivered at all 
times of VT/VF development, while ICD did not de-
Table 5. Probability without rhythm disturbance by Kaplan Maier method
Rhythm disturbance
TIME
p  1.month
follow up
3.month follow up 6.month follow up 12.month follow up
NSVT
DFT Performed 75% 60% 60% 60%
0.632
DFT Not Performed 90% 80% 70% 45%
AF
DFT Performed 70% 70% 70% 70%
0.462
DFT Not Performed 85% 85% 80% 80%
VT
DFT Performed 90% 90% 85% 85%
0.991
DFT Not Performed 90% 85% 85% 85%
VF
DFT Performed 100% 100% 100% 100%
0.037
DFT Not Performed 95% 95% 95% 80%
All Events
DFT Performed 60% 45% 40% 40%
0.893
DFT Not Performed 75% 60% 55% 35%
NSVT- non-sustained VT; AF – atrial fibrillation; VT – ventricular tachycardia; VF-ventricular fibrillation470 NATAŠA KOVAČEVIĆ-KOSTIĆ ET AL.
liver any kind of therapy (neither ATP nor DC shock) 
in cases when NSVT or AF were the cause of rhythm 
disturbances, showing that appropriate shock occur-
rence was 100% in both groups. This speaks in favor 
of the hypothesis that DFT does not predict shock 
appropriateness, hence the better performance and 
efficacy of ICD. All VT episodes were terminated 
with ATP, and VF arrhythmias in both groups were 
terminated  with  a  single  DC  shock,  showing  that 
appropriate therapy effectiveness was 100%. In the 
literature, the percentage of inappropriate shocks is 
32% (Brady et al., 2005).
Figs. 1. Kaplan Maier curves of event occurenceDEFIBRILLATION THRESHOLD TESTING 471
Present arguments in favor of DFT are obscure 
and questionable (Bianchi et al., 2011). The scientific 
community is divided between those in favor of DFT 
and those against it. According to Bianchi et al., in 
medical centers across Italy about 66% of device im-
plantation has been done without DFT (Bianchi et 
al., 2011). According to the authors, the two main 
reasons for not performing DFT are center practice 
and primary prevention (Bianchi et al., 2011). This 
study showed that Italian doctors are concerned for 
the safety of patients undergoing ICD implantation 
for primary prevention with left ventricular dysfunc-
tion  because  of  the  potential  deleterious  effect  of 
DFT due to their increased susceptibility to adverse 
events caused by VF induction (Bianchi et al., 2011). 
According to the European Heart Rhythm Associa-
tion Survey, 19.3% of the 57 centers that responded 
to the Survey do not perform DFT during implanta-
tion procedures (Morgan, 2011). In the past we have 
noticed during follow-up visits that in patients in 
whom DFT was not performed due to their bad clin-
ical condition during ICD implantation for primary 
prevention, the detection and therapy of ventricular 
tachyarrhythmias was adequate. This has led us to 
question our practice of DFT during ICD implanta-
tion. 
Some of the reasons against DFT are the follow-
ing: literature data suggest that induced VF is dif-
ferent from spontaneous VF. The latter is faster and 
more irregular than the former (Lever et al., 2007). 
This fact is important because the probability of de-
fibrillation correlates with VF regularity (Makikallio 
et al., 2002). The characteristics of induced VF at ICD 
implantation are more similar to the process that oc-
curs during electrocution and commotio cordis, while 
spontaneous primary VF is mostly caused by myo-
cardial ischemia (Viskin, 2008). Features of induced 
VF, such as cycle length and vector-index, differ from 
one mode of induction to another; these features also 
reflect VF organization, which affects probability of 
defibrillation; hence the mode of VF induction has 
an impact on DFT (Viskin, 2008). Ventricular fibril-
lation regularity also correlates with the probability 
for  defibrillation.  There  is  a  study  suggesting  that 
spontaneous VF is faster and with a lower degree 
of regularity than induced VF in the same patients 
(Viskin, 2008). Some studies on animals also suggest 
that the energy level required to terminate VF is not 
the same for induced VF and spontaneous ischemic 
VF that we are trying to treat, the latter being high-
er (Viskin, 2008), (Qin et al., 2002), (Walcott et al., 
2002). The fact that physicians test the performance 
of ICDs at the implantation by inducing VF with the 
assumption that this arrhythmia mimics clinical ar-
rhythmia, questions the medical significance and rel-
evance of the whole process, when the clinical event 
we are inducing is completely pathophysiologically 
and morphologically different from the one we are 
trying to treat.
Viskin and Rosso pointed out in their article that 
the majority of implanted ICDs will never treat spon-
taneous VF (Viskin, 2008). The same article suggests 
that 40% of implanted ICDs would detect and treat 
VT/VF during one battery lifetime. Our results show 
that 22.5% of the implanted ICDs in our study popu-
lation detected and treated VT/VF. ICD devices use 
lithium-vanadium batteries, which are a more reli-
able source of energy and have a predictable exploi-
tation time. One battery lifetime is approximately 6 
years long, but can vary depending on the frequency 
of DC shock delivery. In our study, a battery status 
check of all ICD devices was performed at each fol-
low up visit. Since the need for DC shock therapy 
was not high in our study groups, none of the ICD 
devices needed battery change during the one-year 
follow-up period. The battery life expectancy of all 
implanted ICD devices in the present cohort of pa-
tients was over five years, so it was not realistic to ex-
pect any significant impact on battery life during the 
one-year follow-up period in both groups of patients. 
Also those patients that develop ventricular tachyar-
rhythmias are more likely to develop VT rather than 
VF; with ICD algorithm programming these VT epi-
sodes could be safely terminated with ATP without 
the need for DC shock (Viskin, 2008). Of the 13 epi-
sodes of ventricular tachyarrhythmias that occurred 
in our study groups during the one-year follow-up, 
8 were VT episodes that successfully responded to 
antitachycardia pacing and did not require DC shock 
for termination. 472 NATAŠA KOVAČEVIĆ-KOSTIĆ ET AL.
In our study, we had no deaths reported within 
the 12 months of follow-up. Literature data concern-
ing long-term mortality are equivocal. In the article 
by Pires et al, the results indicated that overall mor-
tality was higher in the DFT no testing group. This 
result was overturned by the authors themselves with 
the fact that “sicker” patients (lower left ventricular 
ejection  fraction,  ischemic/non-ischemic  cardiac 
myopathy, higher New York Heart Association-NY-
HA class) were included in the no-DFT-group, sug-
gesting that the higher overall mortality may be influ-
enced by other factors and not primarily by a lack of 
DFT, hence device therapy failure (Pires, 2006). The 
main cause of death in patients with NYHA class IV 
is progression of heart failure (Abraham, 2007). Our 
patients were without statistical significance for these 
comorbidities. While in our study prior ischemia was 
determined by Cox regression analysis as a predic-
tor of difference in probability for developing NSVT, 
and digoxin therapy for the development of any of 
the rhythm disturbances, the Cox regression model 
did not establish DFT as a predictor of event occur-
rence (possible cause of inhomogeneity between the 
DFT- and no-DFT-groups in the severity of the dis-
ease) that could cause a possible pro-DFT bias. 
The process of DFT carries its consequences that 
reflect the induction of VF and subsequent shock. It 
can cause myocardial damage, cardiac arrest caused 
by  refractory  VF,  electromechanical  dissociation, 
transient ischemic events, and patients with atrial 
fibrillation  may  develop  embolic  stroke.  Unfortu-
nately, sometimes it may even result in death (Calvi 
et al., 2010). In the article “the Canadian experience” 
by Birnie et al., 35 of 19,067 patients (0.18%) had a 
complication related to DFT. There were 3 deaths 
reported, 2 of which were due to electromechanical 
dissociation caused by VF induction, and 1 that was 
due to embolic stroke. Five (0.026%) patients suffered 
a cerebrovascular accident or transitory ischemic at-
tack within 24 hours of DFT. Prolonged resuscitation 
was required in 27 (0.14%) patients (Birnie et al., 
2008). We had no complications reported in either 
group of patients. Having all the above-mentioned 
in mind, it is understandable why many physicians 
have decided to abandon DFT. The number of ven-
tricular tachyarrhythmic events in patients under-
going ICD implantation for primary prevention is 
usually smaller than the number of events in patients 
undergoing ICD implantation for secondary preven-
tion (Capoferri et al., 2008), so a larger number of 
patients is needed. Our results are preliminary and 
we will continue to evaluate this type of patients in 
increasing numbers which will increase the statisti-
cal significance of our results.
Study limitations
There were several limitations to our study that need 
to be addressed. The first regards the number of pa-
tients, while the second regards the length of the fol-
low-up periods. During the period of this study, this 
was the number of patients that were treated at our 
Clinic for primary prevention. Therefore, we could 
not have a greater number of patients; nevertheless, 
we wanted to share our experience with others. An 
increase in the number of individuals would prob-
ably influence the statistical significance of the ob-
tained results, as would a longer follow-up period. 
CONCLUSION
The results of this pilot study indicate that DFT may 
not be a predictor for successful ICD detection and 
therapy of ventricular tachyarrhythmias, and that the 
standard practice of DFT during ICD implantation 
in primary prevention could be re-evaluated. How-
ever, because of the small number of patients and a 
follow-up period of 12 months, it is not possible to 
draw a definite conclusion. This study is just a small 
contribution to the an ongoing debate on whether to 
perform DFT or not, and there is a need for a ran-
domized prospective trial with a larger number of 
patients and a longer follow up period.
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